Last updated on June 2020

An Efficacy Study Comparing Brigatinib Versus Alectinib in Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small-Cell Lung Cancer (NSCLC) Participants Who Have Progressed on Crizotinib


Brief description of study

The purpose of this study is to compare the efficacy of brigatinib versus alectinib in participants with ALK+ locally advanced or metastatic NSCLC who have progressed on crizotinib as evidenced by progression-free survival (PFS) as assessed by response evaluation criteria in solid tumors (RECIST) v1.1.

Detailed Study Description

The drug being tested in this study is called brigatinib. Brigatinib has been demonstrated to benefit people with ALK+ NSCLC.

The comparator drug is called alectinib. Alectinib has been demonstrated to benefit people with ALK+ NSCLC. Both drugs belong to a class of drugs called anaplastic lymphoma kinase (ALK) inhibitors. Both drugs are taken by mouth. Both drugs are approved by the United States Food and Drug Administration (US FDA).

The study will enroll approximately 246 participants. Participants will be randomly assigned (by chance, like flipping a coin) in 1:1 ratio to one of the two treatment groups:

  • Brigatinib
  • Alectinib

All participants will be asked to take brigatinib or alectinib at the same time each day throughout the study.

This multi-center trial will be conducted the United States, Argentina, Austria, Canada, Chile, China, Croatia, France, Germany, Greece, Hong Kong, Italy, Mexico, Romania, Russia, South Korea, Spain, Sweden, Taiwan, Thailand. The overall time to participate in this study is 5 years. Participants will make multiple visits to the clinic, and 30 days after last dose of study drug for a follow-up assessment.

Clinical Study Identifier: NCT03596866

Find a site near you

Start Over

Virginia Cancer Specialists

Fairfax, VA United States
  Connect »

Hopital Foch

Suresnes, France
  Connect »

Gustave Roussy

Villejuif cedex, France
  Connect »

Hopital Albert Michallon

Grenoble Cedex 9, France
  Connect »

Queen Mary Hospital

Hong Kong, Hong Kong
  Connect »

National Cancer Center

Goyang-si, Korea, Republic of
  Connect »

Ajou University Hospital

Suwon, Korea, Republic of
  Connect »

Ulsan University Hospital

Ulsan, Korea, Republic of
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Medica Sur

Ciudad de Mexico, Mexico
  Connect »

Euromedservice

Saint-Petersburg, Russian Federation
  Connect »

VitaMed

Moscow, Russian Federation
  Connect »

Leningrad Regional Clinical Hospital

Saint Petersburg, Russian Federation
  Connect »

Center of Palliative Medicine - Devita

Saint Petersburg, Russian Federation
  Connect »

Klinikum Klagenfurt Am Worthersee

Klagenfurt am Wörthersee, Austria
  Connect »

Clinica Ultra Sound Diagnostic 4D

Pyatigorsk, Russian Federation
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.